Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Grepafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TOP2A | P11388 | 3/20 | 0.52 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Grepafloxacin SCHEMBL29419670 | 1.00 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL1230941 | 1.00 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL2636690 | 1.00 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL34155 | 0.99 | KCNH2 (1.00) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL34157 | 0.99 | KCNH2 (1.00) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL29695614 | 0.99 | KCNH2 (1.00) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL34156 | 0.99 | KCNH2 (1.00) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL7763536 | 0.98 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| Grepafloxacin SCHEMBL7763531 | 0.98 | KCNH2 (0.98) | KCNH2HRH3KDM4EALDH1A1HPGD | |
| SCHEMBL9501145 | 0.92 | KCNH2 (0.87) | KCNH2HRH3KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 775 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-3684373-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | Atopic Medical, LLC (US) | 2020-07-29 | — | — | EP | claimed |
| WO-2019060553-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | Atopic Medical, LLC (US) | 2019-03-28 | — | — | WO | claimed |
| US-20190083518-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL, INC. | 2019-03-21 | — | — | US | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| EP-2413974-B1 | CONJUGATED ANTIMICROBIAL AGENTS | TECHNION RES & DEV FOUNDATION (IL) | 2016-03-23 | — | — | EP | claimed |
| US-9149536-B2 | Conjugated antimicrobial agents | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2015-10-06 | — | — | US | claimed |
| US-20140357591-A1 | CONJUGATED ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2014-12-04 | — | — | US | claimed |
| US-20140271923-A1 | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions | REID CHRISTOPHER BRIAN (US) | 2014-09-18 | — | — | US | claimed |
| US-8642089-B2 | Melt extrusion of salts of active ingredients | EVONIK ROEHM GMBH (DE) | 2014-02-04 | — | — | US | claimed |
| EP-2413974-A1 | CONJUGATED ANTIMICROBIAL AGENTS | Technion Research & Development Foundation Ltd. (IL) | 2012-02-08 | — | — | EP | claimed |
| US-20120018334-A1 | CONJUGATED ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2012-01-26 | — | — | US | claimed |
| WO-2010113151-A1 | CONJUGATED ANTIMICROBIAL AGENTS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-10-07 | — | — | WO | claimed |
| EP-1478344-B1 | MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS | ROEHM GMBH (DE) | 2007-05-23 | — | — | EP | claimed |
| US-20040253314-A1 | Melt extrusion of salts of active ingredients | ROEHM GMBH (DE) | 2004-12-16 | — | — | US | claimed |
| EP-1478344-A2 | MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS | Röhm GmbH & Co. KG (DE) | 2004-11-24 | — | — | EP | claimed |
| WO-2003072083-A2 | MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS | Röhm GmbH & Co. KG (DE) | 2003-09-04 | — | — | WO | claimed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | claimed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | KCNH2 2845/4885HRH3 3492/4885KDM4E 4014/4885 |
| US-20140357591-A1 | CONJUGATED ANTIMICROBIAL AGENTS | OGT, IMMT, DNTT | KCNH2 4688/4885HRH3 4129/4885KDM4E 3478/4885 |
| US-20120018334-A1 | CONJUGATED ANTIMICROBIAL AGENTS | OGT, IMMT, DNTT | KCNH2 4688/4885HRH3 4129/4885KDM4E 3478/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | KCNH2 3557/4885HRH3 685/4885KDM4E 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.